NYSE: HAE
Haemonetics Corp Stock

$60.64+1.30 (+2.19%)
Updated Feb 10, 2025
HAE Price
$60.64
Fair Value Price
N/A
Market Cap
$3.05B
52 Week Low
$58.80
52 Week High
$97.97
P/E
23.69x
P/B
3.36x
P/S
2.84x
PEG
0.61x
Dividend Yield
N/A
Revenue
$1.37B
Earnings
$130.07M
Gross Margin
53.3%
Operating Margin
13.14%
Profit Margin
9.5%
Debt to Equity
1.79
Operating Cash Flow
$129M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HAE Overview

Haemonetics Corporation provides blood and plasma supplies and services in the U.S. and internationally. Offerings include donor products marketed to the blood donation industry, and products are marketed to the surgical suite for patient blood loss management. The company was founded in 1971 and is headquartered in Boston, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine HAE's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

A
Value
C
Growth
C
Momentum
D
Sentiment
C
Safety
C
Financials
B
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
A
HAE
Ranked
#25 of 49

Top Ranked Stocks in Industry

View Top Medical Stocks

Be the first to know about important HAE news, forecast changes, insider trades & much more!

HAE News

Overview

Due Diligence Score

–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HAE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HAE ($60.64) is trading above its intrinsic value of $47.48, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HAE is good value based on its earnings relative to its share price (23.69x), compared to the US market average (31x)
P/E vs Market Valuation
HAE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more HAE due diligence checks available for Premium users.

Valuation

HAE price to earnings (PE)

For valuing profitable companies with steady earnings

Company
23.69x
Industry
40.12x
Market
31x
HAE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HAE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

HAE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
3.36x
Industry
4.11x
HAE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HAE price to earnings growth (PEG)

For valuing profitable companies with growth potential

HAE is good value based... subscribe to Premium to read more.
PEG Value Valuation

HAE's financial health

Profit margin

Revenue
$348.5M
Net Income
$37.5M
Profit Margin
10.8%
HAE's Earnings (EBIT) of $180.43M... subscribe to Premium to read more.
Interest Coverage Financials
HAE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.5B
Liabilities
$1.6B
Debt to equity
1.79
HAE's short-term assets ($1.01B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HAE's long-term liabilities ($1.37B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HAE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HAE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$43.8M
Investing
-$17.4M
Financing
$1.4M
HAE's operating cash flow ($129.25M)... subscribe to Premium to read more.
Debt Coverage Financials

HAE vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
HAEC$3.05B+2.19%23.69x3.36x
WRBYB$3.20B+0.99%-98.63x9.52x
NVSTB$3.65B-0.09%-2.72x1.19x
XRAYC$3.67B-1.60%-8.92x1.47x
LMATB$2.21B+0.46%52.92x6.69x

Haemonetics Stock FAQ

What is Haemonetics's quote symbol?

(NYSE: HAE) Haemonetics trades on the NYSE under the ticker symbol HAE. Haemonetics stock quotes can also be displayed as NYSE: HAE.

If you're new to stock investing, here's how to buy Haemonetics stock.

What is the 52 week high and low for Haemonetics (NYSE: HAE)?

(NYSE: HAE) Haemonetics's 52-week high was $97.97, and its 52-week low was $58.80. It is currently -38.1% from its 52-week high and 3.13% from its 52-week low.

How much is Haemonetics stock worth today?

(NYSE: HAE) Haemonetics currently has 50,237,466 outstanding shares. With Haemonetics stock trading at $60.64 per share, the total value of Haemonetics stock (market capitalization) is $3.05B.

Haemonetics stock was originally listed at a price of $7.00 in Dec 31, 1997. If you had invested in Haemonetics stock at $7.00, your return over the last 27 years would have been 766.29%, for an annualized return of 8.32% (not including any dividends or dividend reinvestments).

How much is Haemonetics's stock price per share?

(NYSE: HAE) Haemonetics stock price per share is $60.64 today (as of Feb 10, 2025).

What is Haemonetics's Market Cap?

(NYSE: HAE) Haemonetics's market cap is $3.05B, as of Feb 11, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Haemonetics's market cap is calculated by multiplying HAE's current stock price of $60.64 by HAE's total outstanding shares of 50,237,466.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.